Advertisement

Journal of Endocrinological Investigation

, Volume 30, Issue 11, pp 937–943 | Cite as

Association of the peroxisome proliferator-activated receptor-γ2 Pro12Ala but not the C1431T gene variants with lower body mass index in Type 2 diabetes

  • M. Ben Hadj Mohamed
  • N. Mtiraoui
  • I. Ezzidi
  • M. Chaieb
  • T. Mahjoub
  • W. Y. Almawi
Original Articles

Abstract

The peroxisome proliferator-activated receptor-γ (PPARγ) is a nuclear receptor involved in lipid metabolism, adipocyte differentiation and regulation of insulin sensitivity, and is associated with Type 2 diabetes (T2DM). The association of the C1431T silent mutation and the Pro12Ala missense transversion within the PPARY gene with the development of T2DM or obesity has often yielded contradictory results. We examined the association of the PPARY Pro12Ala and C1431T gene variants and their haplotypes with the susceptibility to T2DM. This was a retrospective study involving 491 T2DM patients and 400 age- and gender-matched controls. Pro12Ala and C1431T genotyping was done by PCR-RFLP analysis. Comparable frequencies of the mutant 12Ala (0.07 vs 0.08, p=0.216) and 1431T (0.12 vs 0.10, p=0.189) alleles, and Pro12Ala (p=0.218) and C1431T (p=0.421) genotypes were seen between patients and in non-diabetic control subjects. While no difference was noted in the distribution of Pro12Ala-C1431T haplotypes and genotypes between patients and controls, the PPARY 12Ala, but not 1431T, allele was significantly associated with lower body mass index (BMI) (≤25.0) among patients. Regression analysis confirmed the association of the Pro12Ala (odds ratio =5.340; 95% confidence interval =1.044-27.311) with normal (BMI<25.0) but not with overweight/obesity among T2DM patients. Despite its association with lower BMI among T2DM patients, the PPARY gene does not appear to markedly influence Type 2 diabetes among Tunisian subjects.

Key-words

Diabetes PPARγ mutations haplotypes genotypes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Malecki MT. Genetics of type 2 diabetes mellitus. Diabetes Res Clin Pract 2005, 68: S10–21.PubMedCrossRefGoogle Scholar
  2. 2.
    Freeman H, Cox RD. Type-2 diabetes: a cocktail of genetic discovery. Hum Mol Genet 2006, 15: R202–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. Diabetes 2002, 51: 2341–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Tönjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006, 29: 2489–97.PubMedCrossRefGoogle Scholar
  5. 5.
    Tai ES, Corella D, Deurenberg-Yap M, et al. Differential effects of the C1431T and Pro12Ala PPARγ gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 2004, 45: 674–85.PubMedCrossRefGoogle Scholar
  6. 6.
    Kannisto K, Chibalin A, Glinghammar B, Zierath JR, Hamsten A, Ehrenborg E. Differential expression of peroxisomal proliferator activated receptors alpha and delta in skeletal muscle in response to changes in diet and exercise. Int J Mol Med 2006, 17: 45–52.PubMedGoogle Scholar
  7. 7.
    Sundvold H, Lien S. Identification of a novel peroxisome proliferator-activated receptor (PPAR)γ promoter in man and transactivation by the nuclear receptor RORα1. Biochem Biophys Res Commun 2001, 287: 383–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Yen C-J, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPAR γ) gene in diabetic Caucasians: identification of a Pro12Ala PPAR γ 2 missense mutation. Biochem Biophys Res Comm 1997, 241: 270–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Doney ASF, Fischer B, Cecil JE, et al. Association of the Pro12Ala and C1431 variants of PPARγ and their haplotypes with susceptibility to type 2 diabetes. Diabetologia 2004, 47: 555–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26: 76–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Malecki MT, Frey J, Klupa T, et al. The Pro12Ala polymorphism of PPARγ2 gene and susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract 2003, 62: 105–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Muller YL, Bogardus C, Beamer BA, Shuldiner AR, Baier LJ. A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 2003, 52: 1864–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Jaziri R, Lobbens S, Aubert R, et al. The PPARγ Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 2006, 55: 1157–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Andrulionyte L, Peltola P, Chiasson JL, Laakso M; STOP-NID-DM Study Group. Single nucleotide polymorphisms of PPAR8 in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARγ2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2006, 55: 2148–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Vasseur F, Helbecque N, Lobbens S, et al. Hypoadiponectinemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity evidence for a role of ACDC in diabesity. Diabetologia 2005, 48: 892–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Ghoussaini M, Meyre D, Lobbens S, et al. Implication of the Pro12Ala polymorphism of the PPAR-γ2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet 2005, 6: 11.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Kim KS, Choi SM, Shin SU, Yang HS, Yoon Y. Effects of peroxisome proliferator-activated receptor-γ 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. Metabolism 2004, 53: 1538–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Beamer BA, Yen CJ, Andersen RE. Association of the Pro12Ala variant in the peroxisome proliferator activated receptor-γ 2 gene with obesity in two Caucasian population. Diabetes 1998, 47: 1806–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Cecil JE, Fischer B, Doney AS, et al. The Pro12Ala and C-681G variants of the PPARγ locus are associated with opposing growth phenotypes in young schoolchildren. Diabetologia 2005, 48: 1496–502.PubMedCrossRefGoogle Scholar
  20. 20.
    Al-Shali KZ, House AA, Hanley AJ, et al. Genetic variation in PPARγ encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis. Stroke 2004, 35: 2036–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Hara K, Okada T, Tobe K, et al. The Pro12Ala polymorphism in PPARγ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000, 271: 212–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Zouari Bouassida K, Chouchane L, Jellouli K, et al. The peroxisome proliferator activated receptorγ2 (PPARγ2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients. Diabetes Metab 2005, 31: 119–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Gonzalez Sanchez JL, Serrano Rios M, Fernandez Perez C, Laakso M, Martinez Larrad MT. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002, 147: 495–501.PubMedCrossRefGoogle Scholar
  24. 24.
    Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated receptor γ 2 (PPARγ2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003, 52: 3010–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Li L, Cheng LX, Nsenga R, He MA, Wu TC. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-γ 2 and myocardial infarction in the Chinese Han population. Clin Cardiol 2006, 29: 300–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Doney A, Fischer B, Frew D, et al. Haplotype analysis of the PPARγ Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 2002, 3: 21.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Douglas JA, Erdos MR, Watanabe RM, et al. The peroxisome proliferator-activated receptor-γ2 Pro12Ala variant. Association with type 2 diabetes and traits differences. Diabetes 2001, 50: 886–90.PubMedCrossRefGoogle Scholar
  28. 28.
    Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20: 284–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 2001, 276: 41245–54.PubMedCrossRefGoogle Scholar
  30. 30.
    Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 1999, 111: 241–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Lei HH, Chen MH, Yang WS, et al. Peroxisome proliferator-activated receptor γ2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism 2000, 49: 1267–70.PubMedCrossRefGoogle Scholar
  32. 32.
    Hasstedt SJ, Ren QF, Teng K, Elbein SC. Effect of the peroxisome proliferator-activated receptor-γ2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 2001, 86: 536–41.PubMedGoogle Scholar
  33. 33.
    Ek J, Andersen G, Urhammer SA, et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 2001, 44: 1170–6.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2007

Authors and Affiliations

  • M. Ben Hadj Mohamed
    • 1
  • N. Mtiraoui
    • 1
  • I. Ezzidi
    • 1
  • M. Chaieb
    • 2
  • T. Mahjoub
    • 1
  • W. Y. Almawi
    • 3
  1. 1.Research unit of Haematological and Autoimmune Diseases, Faculty of Pharmacy, MonastirCenter UniversityTunisia
  2. 2.Endocrinology and Diabetic Service, CHU Farhat Hached of SousseArabian Gulf UniversityManama
  3. 3.Department of Medical Biochemistry, College of Medicine and Medical SciencesArabian Gulf UniversityManama

Personalised recommendations